AI-designed drug appears to turn back the body's biological clock in early trial
Insilico Medicine's AI-designed drug rentosertib showed reduced predicted biological age in IPF trial blood analysis, published in Nature Biotechnology.
Insilico Medicine reported that rentosertib, an AI-designed drug candidate in Phase III trials for idiopathic pulmonary fibrosis, showed reduced predicted biological age in blood protein analysis of 42 trial patients. Six independent aging-clock models built by teams at Harvard, Oxford, Beijing, and Insilico all predicted lower biological age versus placebo, with drops of three to four years by week 4 and up to six years on one clock. The drug targets TNIK and was developed with two generative AI systems in about 18 months; Eli Lilly recently invested in the company. Experts including Eric Topol and Harvard's Vadim Gladyshev called the results encouraging but not definitive, citing small sample size.